The latest announcement is out from Elanco Animal Health ( (ELAN) ).
Elanco Animal Health announced changes to its Board of Directors, with several members, including William Doyle, stepping down. Doyle’s resignation is linked to a new research agreement with Elanco through his entity, WEDterinary LLC, focusing on novel therapies for chronic kidney disease and life extension in pets. The agreement aims to leverage gene therapy and AI, enhancing Elanco’s innovation pipeline and positioning the company for long-term growth in the animal health industry.
More about Elanco Animal Health
Elanco Animal Health Incorporated is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. With a 70-year heritage, Elanco focuses on creating value for farmers, pet owners, veterinarians, and society, driven by a vision of enriching life through food and companionship.
YTD Price Performance: -13.36%
Average Trading Volume: 4,692,802
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.16B
For a thorough assessment of ELAN stock, go to TipRanks’ Stock Analysis page.